Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1013

1.

Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.

Woo HY, Choi JY, Jang JW, You CR, Bae SH, Yoon SK, Yang JM, Choi SW, Han NI, Kim DG.

J Med Virol. 2008 Nov;80(11):1891-9. doi: 10.1002/jmv.21324.

PMID:
18814257
2.

[Prevention and treatment of hepatitis B virus reinfection after liver transplantation].

Liu J, Wu GC, Zhang ZT, Wu P, Zhang D, Sun MC, Gao DC, Wang Y, Jia JD, Wang BE.

Zhonghua Wai Ke Za Zhi. 2005 Aug 1;43(15):976-9. Chinese.

PMID:
16194352
3.

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, Bassendine M, O'Grady JG, Portmann BC, Anschuetz G, Barrett CA, Williams R, Atkins M.

J Hepatol. 2001 Jun;34(6):888-94.

PMID:
11451173
4.
5.

Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.

Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW; Australasian Liver Transplant Study Group.

Gastroenterology. 2007 Mar;132(3):931-7. Epub 2007 Jan 5.

PMID:
17383422
6.

Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.

Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI, Tong MJ, Busuttil RW.

Liver Transpl. 2009 Nov;15(11):1525-34. doi: 10.1002/lt.21882.

8.
9.

Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.

Lu SC, Yan LN, Li B, Wen TF, Zhao JC, Cheng NS, Liu C, Liu J, Wang XB, Li XD, Qin S, Zhao LS, Lei BJ, Zhang XH.

Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):26-32.

10.

Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.

Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbes CD, Elias N, Cantarovich M, Cleland P, Metrakos P, Meakins JL.

Ann Surg. 1997 Sep;226(3):356-65; discussion 365-8.

11.

Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.

Seehofer D, Rayes N, Steinmüller T, Müller AR, Jonas S, Settmacher U, Neuhaus R, Berg T, Neuhaus P.

Z Gastroenterol. 2002 Sep;40(9):795-9.

PMID:
12215948
12.

Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.

Karasu Z, Ozacar T, Akyildiz M, Demirbas T, Arikan C, Kobat A, Akarca U, Ersoz G, Gunsar F, Batur Y, Kilic M, Tokat Y.

Antivir Ther. 2004 Dec;9(6):921-7.

PMID:
15651751
13.

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis.

Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F, Rizzetto M.

J Hepatol. 2001 Jun;34(6):903-10.

PMID:
11451175
14.

Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, Ferretti S, Iappelli M, Rossi M, Rivanera D, Lilli D, Mancini C, Attili A, Berloco P.

Transplant Proc. 2004 Apr;36(3):535-8.

PMID:
15110584
15.

[Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].

Yang Y, Yang Y, Zhang J, Yi HM, Lu MQ, Cai CJ, Li X, Jiang N, Xu C, Li H, Wang GS, Yi SH, Zhang JF, Jiang H, Yang Q, Chen GH.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Oct;28(10):1810-2. Chinese.

16.
17.

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.

Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer DG, Ghobrial RM, Busuttil RW, Martin P.

Liver Transpl. 2000 Nov;6(6):741-8.

18.
19.

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.

Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW.

Hepatology. 1998 Aug;28(2):585-9.

PMID:
9696028
20.

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL.

Antivir Ther. 2007;12(8):1295-303.

PMID:
18240869
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk